These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 22508169)

  • 1. Is isoniazid for 6 months more cost-effective than isoniazid for 9 months?
    Pina JM; Clotet L; Sala MR; Ferrer A; Arias C; Domínguez A
    Int J Tuberc Lung Dis; 2012 Jun; 16(6):768-73. PubMed ID: 22508169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials.
    Esfahani K; Aspler A; Menzies D; Schwartzman K
    Int J Tuberc Lung Dis; 2011 Oct; 15(10):1340-6. PubMed ID: 22283892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection.
    Pina JM; Clotet L; Ferrer A; Sala MR; Garrido P; Salleras L; Domínguez A
    Respir Med; 2013 May; 107(5):768-77. PubMed ID: 23490222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
    Doan TN; Fox GJ; Meehan MT; Scott N; Ragonnet R; Viney K; Trauer JM; McBryde ES
    J Antimicrob Chemother; 2019 Jan; 74(1):218-227. PubMed ID: 30295760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication.
    Denholm JT; McBryde ES; Eisen D; Street A; Matchett E; Chen C; Shultz TR; Biggs B; Leder K
    Intern Med J; 2017 Dec; 47(12):1433-1436. PubMed ID: 29224209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.
    Shepardson D; Marks SM; Chesson H; Kerrigan A; Holland DP; Scott N; Tian X; Borisov AS; Shang N; Heilig CM; Sterling TR; Villarino ME; Mac Kenzie WR
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1531-7. PubMed ID: 24200264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latent tuberculosis infection in children: a call for revised treatment guidelines.
    Finnell SM; Christenson JC; Downs SM
    Pediatrics; 2009 Mar; 123(3):816-22. PubMed ID: 19255008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population.
    Jiménez-Fuentes MA; de Souza-Galvao ML; Mila Augé C; Solsona Peiró J; Altet-Gómez MN
    Int J Tuberc Lung Dis; 2013 Mar; 17(3):326-32. PubMed ID: 23407221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
    Huang YW; Yang SF; Yeh YP; Tsao TC; Tsao SM
    Medicine (Baltimore); 2016 Aug; 95(34):e4126. PubMed ID: 27559940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of latent tuberculosis infection: An update.
    Lobue P; Menzies D
    Respirology; 2010 May; 15(4):603-22. PubMed ID: 20409026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB.
    Aspler A; Long R; Trajman A; Dion MJ; Khan K; Schwartzman K; Menzies D
    Thorax; 2010 Jul; 65(7):582-7. PubMed ID: 20627913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is isoniazid safe for liver transplant candidates with latent tuberculosis?
    Stucchi RS; Boin IF; Angerami RN; Zanaga L; Ataide EC; Udo EY
    Transplant Proc; 2012 Oct; 44(8):2406-10. PubMed ID: 23026607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on cost-effectiveness of a 12-dose regimen for latent tuberculous infection at new rifapentine prices.
    Shepardson D; MacKenzie WR
    Int J Tuberc Lung Dis; 2014 Jun; 18(6):751. PubMed ID: 24903950
    [No Abstract]   [Full Text] [Related]  

  • 14. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
    Sun HY; Huang YW; Huang WC; Chang LY; Chan PC; Chuang YC; Ruan SY; Wang JY; Wang JT
    Tuberculosis (Edinb); 2018 Jul; 111():121-126. PubMed ID: 30029896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Dec; 60(48):1650-3. PubMed ID: 22157884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of 12-dose LTBI regimen improved following advocacy to lower the price of rifapentine.
    Frick M; Seaworth B; McKenna L; Elnour T; Lee C
    Int J Tuberc Lung Dis; 2014 Nov; 18(11):1386. PubMed ID: 25299876
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of treating latent tuberculous infection: a step towards elimination?
    Diel R; Loddenkemper R; Sotgiu G; Migliori GB
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1515. PubMed ID: 24200259
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of tuberculosis screening and isoniazid treatment in the TB/HIV in Rio (THRio) Study.
    Azadi M; Bishai DM; Dowdy DW; Moulton LH; Cavalcante S; Saraceni V; Pacheco AG; Cohn S; Chaisson RE; Durovni B; Golub JE
    Int J Tuberc Lung Dis; 2014 Dec; 18(12):1443-8. PubMed ID: 25517809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of isoniazid chemoprevention in close contacts.
    Diel R; Nienhaus A; Schaberg T
    Eur Respir J; 2005 Sep; 26(3):465-73. PubMed ID: 16135730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of latent tuberculosis infection].
    Fraisse P;
    Rev Mal Respir; 2012 Apr; 29(4):579-600. PubMed ID: 22542415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.